Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.013
Neutral
RSI(14)
48.360
Neutral
STOCH(KDJ)(9,3,3)
31.223
Sell
ATR(14)
0.165
High Vlolatility
CCI(14)
-53.445
Neutral
Williams %R
55.571
Sell
TRIX(12,20)
0.120
Sell
StochRSI(14)
41.712
Buy
BioLine RX Ltd
BLRX2.980USD
+0.060+2.05%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
12.97MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of BioLine RX Ltd
Currency: USD Updated: 2026-02-06Key Insights
BioLine RX Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 182 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.33.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioLine RX Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
BioLine RX Ltd Highlights
StrengthsRisks
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.94M.
Overvalued
The company’s latest PE is -2.06, at a high 3-year percentile range.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
20.333
Target Price
+596.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of BioLine RX Ltd is 5.92, ranking 312 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 427.00K, representing a year-over-year decrease of 91.36%, while its net profit experienced a year-over-year decrease of 83.22%.
Score
Financials
5.64
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.78
Operational Efficiency
2.83
Growth Potential
5.26
Shareholder Returns
7.07
BioLine RX Ltd's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of BioLine RX Ltd is 7.46, ranking 119 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.06, which is -62.86% below the recent high of -0.77 and -98535.22% above the recent low of -2032.77.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 182/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of BioLine RX Ltd is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 26.00, with a high of 40.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
20.333
Target Price
+596.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
BioLine RX Ltd
BLRX
2
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of BioLine RX Ltd is 3.43, ranking 364 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.21 and the support level at 2.73, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.004
Sell
MA10
3.044
Sell
MA20
2.973
Buy
MA50
3.054
Sell
MA100
3.369
Sell
MA200
3.697
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioLine RX Ltd is 2.97, ranking 182 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.30
VaR
+7.18%
240-Day Maximum Drawdown
+53.29%
240-Day Volatility
+103.84%
Return
Best Daily Return
60 days
+7.69%
120 days
+16.16%
5 years
+52.98%
Worst Daily Return
60 days
-6.92%
120 days
-7.18%
5 years
-40.87%
Sharpe Ratio
60 days
-0.85
120 days
-0.86
5 years
-0.44
Risk Assessment
Maximum Drawdown
240 days
+53.29%
3 years
+97.52%
5 years
+98.76%
Return-to-Drawdown Ratio
240 days
-0.35
3 years
-0.31
5 years
-0.20
Skewness
240 days
+1.97
3 years
-0.30
5 years
+0.35
Volatility
Realised Volatility
240 days
+103.84%
5 years
+103.72%
Standardised True Range
240 days
+9.62%
5 years
+113.63%
Downside Risk-Adjusted Return
120 days
-168.94%
240 days
-168.94%
Maximum Daily Upside Volatility
60 days
+39.23%
Maximum Daily Downside Volatility
60 days
+38.57%
Liquidity
Average Turnover Rate
60 days
+0.01%
120 days
+0.03%
5 years
--
Turnover Deviation
20 days
-97.33%
60 days
-93.56%
120 days
-68.42%
Peer Comparison
Biotechnology & Medical Research
BioLine RX Ltd
BLRX
5.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
